A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)

NCT01126580 · Completed

Last updated 2026-05-28

This clinical trial tested a new treatment in adults with type 2 diabetes to see how it affects blood sugar levels over 26 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 807 people

Who can join Ages 18+ · all sexes

Timeline Started 2010-05 · est. completion 2012-06

Where 91 sites · Argentina, Brazil, Canada, Croatia, Czechia, Finland, France, Germany, India, Mexico, Poland, Puerto Rico, Romania, Slovakia, South Africa, South Korea, Spain, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT01126580 ↗

Description as written by the study sponsor.

The purpose of this study is to determine if LY2189265 is safe and effective in reducing glycosylated hemoglobin (HbA1c) as compared to metformin in participants with Type 2 Diabetes.

Treatments tested

Metformin Drug
LY2189265 also known as Dulaglutide Drug
Placebo (oral) Drug
Placebo (subcutaneous) Drug

Main thing measured	Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01126580 ↗